Nasal Cannula System Alleviates Respiratory Distress
By HospiMedica International staff writers Posted on 22 Oct 2018 |
Image: A sophisticated nasal cannula helps relieve respiratory distress (Photo courtesy of Vapotherm).
An updated non-invasive ventilation system augments breathing in patients suffering from respiratory distress in the hospital setting.
The Vapotherm (Exeter, NC, USA) Precision Flow Plus Hi-VNI system is designed to flush out carbon dioxide (CO2) laden and oxygen (O2) depleted exhaled air from the respiratory dead space in the upper airway of spontaneously breathing patients, replacing it with optimally humidified O2 rich breathing gas delivered through a high flow nasal cannula (HFNC). A small-bore cannula and circuit facilitate more efficient dead space washout, with a resulting improvement in ventilation efficiency that reduces the work of breathing in such patients, relieving symptoms.
The Precision Flow Plus optimizes Hi-VNI technology by controlling O2 flow (up to 40 L/minute), O2 concentration, and temperature with a single button, integration with nurse call systems (including alarms), connectivity with the patient’s electronic medical record (EMR) to improve workflow and simplify charting, and a new approach to standby modes that enhances usability. Since no mask is present, patients are able to eat, drink, speak, participate in their care, and avoid mask-related risks of claustrophobia, aspiration, and pressure ulcers.
“Hi-VNI Technology has become an important tool for treating patients in undifferentiated respiratory distress,” said Joe Army, CEO of Vapotherm. “Our customers like having one simple tool to treat hypercapnia, hypoxia, and dyspnea. They also appreciate the convenience of a tool safe enough to be started high for maximum results, and then de-escalated as symptoms subside.”
“Many patients with respiratory distress have difficulty with the full face mask. They can become claustrophobic, making the respiratory failure worse,” said Aaron Boyd, MBA, MD, chief medical officer of Norman Regional Health System (OK, USA). “Vapotherm's technology helps our clinicians safely and efficiently treats these patients much more comfortably and less invasively.”
A recent clinical study of 204 patients at five U.S. emergency departments showed that Vapotherm Hi-VNI Technology is non-inferior to current standard non-invasive positive pressure ventilation (NiPPV) in preventing mechanical ventilation, regardless of the underlying cause of the respiratory distress. By mitigating the risk of mechanical ventilation, the risk of infections, ventilator dependence, and mortality, as well as incurring costs to the hospital, are reduced.
Related Links:
Vapotherm
The Vapotherm (Exeter, NC, USA) Precision Flow Plus Hi-VNI system is designed to flush out carbon dioxide (CO2) laden and oxygen (O2) depleted exhaled air from the respiratory dead space in the upper airway of spontaneously breathing patients, replacing it with optimally humidified O2 rich breathing gas delivered through a high flow nasal cannula (HFNC). A small-bore cannula and circuit facilitate more efficient dead space washout, with a resulting improvement in ventilation efficiency that reduces the work of breathing in such patients, relieving symptoms.
The Precision Flow Plus optimizes Hi-VNI technology by controlling O2 flow (up to 40 L/minute), O2 concentration, and temperature with a single button, integration with nurse call systems (including alarms), connectivity with the patient’s electronic medical record (EMR) to improve workflow and simplify charting, and a new approach to standby modes that enhances usability. Since no mask is present, patients are able to eat, drink, speak, participate in their care, and avoid mask-related risks of claustrophobia, aspiration, and pressure ulcers.
“Hi-VNI Technology has become an important tool for treating patients in undifferentiated respiratory distress,” said Joe Army, CEO of Vapotherm. “Our customers like having one simple tool to treat hypercapnia, hypoxia, and dyspnea. They also appreciate the convenience of a tool safe enough to be started high for maximum results, and then de-escalated as symptoms subside.”
“Many patients with respiratory distress have difficulty with the full face mask. They can become claustrophobic, making the respiratory failure worse,” said Aaron Boyd, MBA, MD, chief medical officer of Norman Regional Health System (OK, USA). “Vapotherm's technology helps our clinicians safely and efficiently treats these patients much more comfortably and less invasively.”
A recent clinical study of 204 patients at five U.S. emergency departments showed that Vapotherm Hi-VNI Technology is non-inferior to current standard non-invasive positive pressure ventilation (NiPPV) in preventing mechanical ventilation, regardless of the underlying cause of the respiratory distress. By mitigating the risk of mechanical ventilation, the risk of infections, ventilator dependence, and mortality, as well as incurring costs to the hospital, are reduced.
Related Links:
Vapotherm
Latest Critical Care News
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration